Apexigen to go public via SPAC merger

Apexigen has announced a SPAC merger with Brookline Capital Acquisition Corporation to help advance its multiple clinical trials.

https://www.globenewswire.com/news-release/2022/03/18/2405858/0/en/Apexigen-and-Brookline-Capital-Acquisition-Corp-Announce-Business-Combination-Agreement-to-Create-Publicly-Listed-Immuno-oncology-Company.html